IDEAYA Biosciences, Inc.

Stage 2 · Advancing · week 14

As of Oct 22, 2026, IDEAYA Biosciences is in Stage 2, the uptrend phase, now in week 14 (since Jul 22, 2026). It closed at $36.12, 15.0% below its 52-week high and above its 200-day average, which is rising.

$36.12

+1.83% today

$3.5B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is IDYA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 35w

S3 16w

S4 36w

S2 27w

S3 13w

S2 13w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 35w → S3 16w → S1 7w → S4 36w → S1 9w → S2 27w → S3 13w → S4 5w → S1 3w → S2 13w current

Total tracked: 165 weeks across 10 stage runs.

IDYA among Biotechnology128th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…128	IDYAIDEAYA Biosciences, Inc.	Stage 2 · wk 14	72	−3.6%

vs 52W High

-15.0%

$27.60 lo$42.48 hi

15.0% below 52W high, pullback range

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 14

1w13w26w

Week 14, proven structure

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

5.9%

200 DMA: $34.12 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.76x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-3.6%

+2.0%

+17.7%

YTD

+6.7%

+23.7%

Scan Membership

Breakout Watch

Latest: 2023-05-10

6 appearances in last 60 days. First seen: 2020-06-18.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 14 · Vol 0.76x

2026-10-21S2

Wk 13 · Vol 0.64x

2026-10-20S2

Wk 13 · Vol 1.21x

2026-10-19S2

Wk 13 · Vol 0.97x

2026-10-16S2

Wk 13 · Vol 0.83x

2026-10-15S2

Wk 13 · Vol 1.72x

2026-10-14S2

Wk 12 · Vol 1.35x

2026-10-13S2

Wk 12 · Vol 1.33x

2026-10-12S2

Wk 12 · Vol 0.57x

2026-10-09S2

Wk 12 · Vol 0.91x

2026-10-08S2

Wk 12 · Vol 0.70x

2026-10-07S2

Wk 11 · Vol 0.71x

Moving averages & range

50 DMA

$37.75

200 DMA

$34.12

52W High

$42.48

52W Low

$27.60

5D Low

$32.85

Resistance levels (recent highs)

20d High

$38.42

60d High

$42.48

120d High

$42.48

250d High

$42.48

Next resistance

+6.4%

to 20d High

ROE

-16.2%

Profit margin -74.8%

Dividend Yield

0.00%

P/B 2.9

IDEAYA Biosciences: quick answers

What stage is IDEAYA Biosciences in?

As of Oct 22, 2026, IDEAYA Biosciences (IDYA) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 22, 2026 and is in week 14. What the four stages mean

Is IDEAYA Biosciences in an uptrend?

Yes. IDEAYA Biosciences is in a Stage 2 uptrend. It trades 5.9% above its 200-day average, which is rising.

How far is IDEAYA Biosciences from its 52-week high?

IDEAYA Biosciences closed at $36.12 on Oct 22, 2026, 15.0% below its 52-week high of $42.48. Its 52-week low is $27.60.

How has IDEAYA Biosciences performed over the past year?

As of Oct 22, 2026, IDEAYA Biosciences is up 23.7% over the past year and up 6.7% so far in 2026.

Which sector and industry is IDEAYA Biosciences in?

IDEAYA Biosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.